Some investors asked if the director of the company could introduce the company's synthetic biotechnology direction and products. Zheng Hai Biotech said on an interactive platform that synthetic biology is an interdisciplinary field based on the concept of engineering, and there are many intersections with regenerative medicine. Currently, the production and preparation process of rhBMP-2, an active factor specifically bound in active biological bone, is a synthetic biological technology; the “research and development of recombinant bioactive protein products” project carried out by the company in cooperation with Jiangsu Jicui Future Food Technology Research Institute Co., Ltd. will further expand the company's technology and product layout in this field. The company will continue to enrich its technical strength, build a comprehensive multi-disciplinary research and development platform for tissue regeneration such as stent materials, factors, and cells, and achieve a three-dimensional layout in the field of regenerative medicine.